HONG KONG – Although authorities only allow studies linked to stem cells at the moment, the launch of China’s first official regulations on stem cell studies may prove to be good news to the country’s cell therapy industry.
HONG KONG – All the recent stock market turbulence notwithstanding, Chinese biopharmaceutical companies continued growing in the first half of 2015, although that growth has slowed.
HONG KONG – Standing out of a crowd of more than 200 next-generation sequencing (NGS) product developers in China, a 20-month-old company raised ¥150 million (US$23 million) in a follow-up series A financing and struck a partnership deal with U.S. genomics leader Illumina Inc.
HONG KONG – Although authorities only allow studies linked to stem cells at the moment, the launch of China's first official regulations on stem cell studies may prove to be good news to the country's cell therapy industry.
HONG KONG – All the recent stock market turbulence notwithstanding, Chinese biopharmaceutical companies continued growing in the first half of 2015, although that growth has slowed.
HONG KONG – Standing out of a crowd of more than 200 next-generation sequencing (NGS) product developers in China, a 20-month-old company raised ¥150 million (US$23 million) in a follow-up series A financing and struck a partnership deal with U.S. genomics leader Illumina Inc.
HONG KONG – China is speeding up approval times and improving the review process for domestic and imported drugs. The ultimate aim of a series of reforms recently announced by the State Council, akin to the cabinet, is to develop a faster and better approvals system that rewards innovation.
